|Bid||2.1900 x 1000|
|Ask||6.0000 x 1100|
|Day's Range||3.8500 - 3.9900|
|52 Week Range||2.2600 - 7.5000|
|Beta (3Y Monthly)||3.76|
|PE Ratio (TTM)||41.28|
|Earnings Date||Feb 6, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
Sue Washer has been the CEO of Applied Genetic Technologies Corporation (NASDAQ:AGTC) since 2002. This analysis aims...
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join AGTC as Chief Medical Officer Brian Krex Named General Counsel GAINESVILLE, Fla. and.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 18, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.